株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺炎連鎖球菌感染症:パイプライン分析

Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 269896
出版日 ページ情報 英文 151 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
肺炎連鎖球菌感染症:パイプライン分析 Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 151 Pages
概要

肺炎連鎖球菌感染症は、肺炎連鎖球菌が原因で引き起こされる感染症です。症状は熱や寒気、発汗、疼痛などが見られます。危険因子としてHIVや糖尿病といった免疫システムの働きを弱める深刻な健康状態、化学療法などのような免疫システムを弱める治療法、そして加齢などが挙げられます。治療には抗生剤が使われます。

当レポートでは、肺炎連鎖球菌感染症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 肺炎連鎖球菌感染症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline Plc
  • ImmunoBiology Limited
  • Lascco SA
  • Melinta Therapeutics, Inc
  • Nabriva Therapeutics AG

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BXN-112
  • CAL-02
  • Cribrostatin-6
  • DEF-201
  • GSK-2830930A
  • lefamulin
  • Monoclonal Antibodies for Streptococcal Pneumoniae Infections
  • Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders
  • Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders
  • pneumococcal serotype 4 and 6A vaccine
  • pneumococcal polysaccharide (13-valent) vaccine
  • pneumococcal vaccine
  • PneumoMab
  • PnuBioVax
  • RXP-873
  • Small Molecule for Respiratory Tract Infections
  • Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia
  • Small Molecules for Streptococcus Pneumoniae Infections
  • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections
  • typhoid + pneumococcal vaccine

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7106IDB

Summary

Global Markets Direct's, 'Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015', provides an overview of the Streptococcus Pneumoniae Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Streptococcus Pneumoniae Infection Overview
  • Therapeutics Development
    • Pipeline Products for Streptococcus Pneumoniae Infection - Overview
    • Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis
  • Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies
  • Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes
  • Streptococcus Pneumoniae Infection - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Streptococcus Pneumoniae Infection - Products under Development by Companies
  • Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes
  • Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development
    • Abera Bioscience AB
    • Allergan Plc
    • Alvogen Korea
    • Arsanis Biosciences GmbH
    • AstraZeneca Plc
    • Beijing Minhai Biotechnology Co., Ltd
    • ContraFect Corporation
    • Daiichi Sankyo Company, Limited
    • Eurocine Vaccines AB
    • FluGen, Inc.
    • GlaxoSmithKline Plc
    • ImmunoBiology Limited
    • Lascco SA
    • Liquidia Technologies, Inc.
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • Mucosis B.V.
    • Panacea Biotec Limited
    • Prometheon Pharma, LLC
    • Sanofi Pasteur SA
    • Serum Institute of India Limited
    • Sinovac Biotech Ltd.
    • SK Chemicals Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Valneva SE
    • Vaxxilon AG
    • Virometix AG
    • Walvax Biotechnology Co., Ltd.
    • Wellstat Vaccines, LLC
    • Wockhardt Limited
  • Streptococcus Pneumoniae Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ab-01 - Drug Profile
    • acorafloxacin hydrochloride - Drug Profile
    • Antibodies for Pneumococcus Infections - Drug Profile
    • ASN-400 - Drug Profile
    • AZ-6142 - Drug Profile
    • CAL-02 - Drug Profile
    • CF-303 - Drug Profile
    • CF-309 - Drug Profile
    • DEF-201 - Drug Profile
    • GSK-2189242A - Drug Profile
    • GSK-2830929A - Drug Profile
    • GSK-2830930A - Drug Profile
    • LCB-010371 - Drug Profile
    • Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile
    • Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile
    • NBP-606 - Drug Profile
    • Nucovac - Drug Profile
    • pneumococcal (13-valent) vaccine - Drug Profile
    • pneumococcal (13-valent) vaccine - Drug Profile
    • pneumococcal (23-valent) vaccine - Drug Profile
    • pneumococcal (monovalent) vaccine - Drug Profile
    • pneumococcal (trivalent) vaccine - Drug Profile
    • pneumococcal [serotype 4 and 6A] vaccine - Drug Profile
    • pneumococcal [TIGR4] vaccine - Drug Profile
    • pneumococcal polysaccharide (13-valent) vaccine - Drug Profile
    • pneumococcal polysaccharide (23-valent) vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcal vaccine - Drug Profile
    • pneumococcus vaccine - Drug Profile
    • PneumoMab - Drug Profile
    • PnuBioVax - Drug Profile
    • PPV-23 - Drug Profile
    • RXP-873 - Drug Profile
    • SIILPCV-10 - Drug Profile
    • SM-295291 - Drug Profile
    • SM-369926 - Drug Profile
    • Small Molecule for Respiratory Tract Infections - Drug Profile
    • Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile
    • Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia - Drug Profile
    • Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile
    • Small Molecules to Inhibit CBPs for Pneumococcus Infections - Drug Profile
    • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
    • streptococcal pneumoniae vaccine - Drug Profile
    • streptococci pneumoniae vaccine - Drug Profile
    • streptococcus pneumonia vaccine - Drug Profile
    • streptococcus pneumoniae vaccine - Drug Profile
    • streptococcus pneumoniae vaccine (whole-cell) - Drug Profile
    • Synthetic Peptides for Bacterial Infections - Drug Profile
    • typhoid + pneumococcal vaccine - Drug Profile
    • V-114 - Drug Profile
    • VMT-1 - Drug Profile
    • WCK-4873 - Drug Profile
  • Streptococcus Pneumoniae Infection - Recent Pipeline Updates
  • Streptococcus Pneumoniae Infection - Dormant Projects
  • Streptococcus Pneumoniae Infection - Discontinued Products
  • Streptococcus Pneumoniae Infection - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Streptococcus Pneumoniae Infection, H2 2015
  • Number of Products under Development for Streptococcus Pneumoniae Infection - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Abera Bioscience AB, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Allergan Plc, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Alvogen Korea, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Arsanis Biosciences GmbH, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by AstraZeneca Plc, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by ContraFect Corporation, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Eurocine Vaccines AB, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by FluGen, Inc., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by ImmunoBiology Limited, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Lascco SA, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Liquidia Technologies, Inc., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Merck & Co., Inc., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Mucosis B.V., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Panacea Biotec Limited, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Prometheon Pharma, LLC, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Sanofi Pasteur SA, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Serum Institute of India Limited, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Sinovac Biotech Ltd., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by SK Chemicals Co., Ltd., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Valneva SE, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Vaxxilon AG, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Virometix AG, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Walvax Biotechnology Co., Ltd., H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Wellstat Vaccines, LLC, H2 2015
  • Streptococcus Pneumoniae Infection - Pipeline by Wockhardt Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Streptococcus Pneumoniae Infection Therapeutics - Recent Pipeline Updates, H2 2015
  • Streptococcus Pneumoniae Infection - Dormant Projects, H2 2015
  • Streptococcus Pneumoniae Infection - Dormant Projects (Contd..1), H2 2015
  • Streptococcus Pneumoniae Infection - Dormant Projects (Contd..2), H2 2015
  • Streptococcus Pneumoniae Infection - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Streptococcus Pneumoniae Infection, H2 2015
  • Number of Products under Development for Streptococcus Pneumoniae Infection - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top